LI-RADS category 5 (LR-5) assessment had an 11 percent higher AUC for detecting hepatocellular carcinoma (HCC) in patients with non-cirrhotic chronic hepatitis C (CHC) in comparison to those with cirrhotic CHC.
The cLung-RADS v2022 model offered a greater than 16 percent increase in the AUC in comparison to Lung-RADS 1.0 and Lung-RADS v2022 systems for predicting the invasiveness of pure ground-glass nodules.
The Naeotom Alpha class of photon-counting computed tomography (PCCT) scanners emphasize significantly reduced scan times and enhanced detection of small abnormalities.
The use of ivonescimab was correlated with a median 5.3-month improvement in progression-free survival (PFS) over pembrolizumab in patients with PD-L1 positive non-small cell lung cancer, according to CT and MRI findings from a phase 3 randomized multicenter trial.
In a comparative study of staging systems for hepatocellular carcinoma, the Barcelona Clinic Liver Cancer (BCLC) system offered the highest likelihood ratio (LR) and lowest Akaike information criteria (AIC) for predicting overall survival after transarterial chemoembolization (TACE) for hepatocellular carcinoma.